Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%71 Debt-to-Equity is 0.05 as of Dec. 2025, which is 72% below its 10-year median of 0.18. GuruFocus rates CPHGF with a GF Score™ of 71/100 and a GF Value™ of $1.10 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 814 Drug Manufacturers companies, Consun Pharmaceutical Group ranks better than 82.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Consun Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:
CPHGF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.18 Max: 0.33
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of Consun Pharmaceutical Group was 0.33. The lowest was 0.05. And the median was 0.18.
CPHGF's Debt-to-Equity is ranked better than 82.43% of 814
companies
in the Drug Manufacturers industry
Industry Median: 0.275
vs CPHGF: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Consun Pharmaceutical Group Debt-to-Equity Related Terms
Consun Pharmaceutical Group Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Debt-to-Equity of 0.05 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Consun Pharmaceutical Group and its competitors. This is 72% below median its historical median of 0.18. Over the past decade, Consun Pharmaceutical Group's Debt-to-Equity has ranged from 0.05 to 0.33. According to the industry distribution chart, Consun Pharmaceutical Group ranks #143 out of 814 companies in the Drug Manufacturers industry, placing it in the top 17.6%.
Is Consun Pharmaceutical Group's Debt-to-Equity too high?
Consun Pharmaceutical Group's current Debt-to-Equity of 0.05 is 72% below median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.33. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Consun Pharmaceutical Group's value of 0.05 is 81.8% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #143 out of 814 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #143 out of 814 companies for Debt-to-Equity. This places Consun Pharmaceutical Group in the top 18% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Consun Pharmaceutical Group's value of 0.05 is 81.8% below this benchmark. Historically, Consun Pharmaceutical Group's own Debt-to-Equity has ranged from 0.05 to 0.33 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.28, Consun Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Debt-to-Equity of 0.05 is 81.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Debt-to-Equity is 0.05, which is 72% below median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.10, compared to a current price of $1.80 — trading 63.6% above its estimated fair value. The current Debt-to-Equity is 0.05, which is 72% below median its 10-year median of 0.18 and 81.8% below the Drug Manufacturers industry median of 0.28. Consun Pharmaceutical Group's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Debt-to-Equity is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 63.6% above its estimated GF Value™ of $1.10.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Debt-to-Equity: 0.05 (72% below median its 10-year median of 0.18)
GF Value™: $1.10 vs. price of $1.80 (63.6% above fair value)
Industry Position: 81.8% below the Drug Manufacturers median (#143 of 814)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
71GF Score
Get the complete analysis for CPHGF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
